An industry reeling from a precarious market is showing signs of stabilizing as the future becomes...
Author - simom
Is a better CAR-T cell therapy option on the horizon?
In vivo CAR-T cell technology has the potential to solve some major issues in the field and could...
Mining clues from a library of brain tissue samples, Cerevance...
Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and...
BMS’ long-standing leukemia blockbuster stares down its first...
Patent disputes in the U.S. and abroad have opened the door to new generics ready for launch as...
Key upcoming events for pharma execs
Trade shows and events focused on the industry’s hot-button topics, technologies and trends.
3 marketing tips for biotechs emerging from stealth
In a crowded biotech market, here’s how your company can stand out to investors.
FDA’s ‘ivory tower thinking’ ignores promising biomarkers...
The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said...
Drugmakers face uphill battle in Medicare negotiation suits
Judges have found fault with drug manufacturers’ First and Fifth Amendment arguments against the...
The PharmaVoice 100: Brand and commercialization pros
Leaders decoding the complex language of drug development to push treatments past the finish line...
Where have all the unicorns gone? A look at 4 billion-dollar...
Not every unicorn company lives up to its $1 billion promise. Here are four worth watching.